Publication
Article
Pharmacy Times
Evaluation and Treatment of Patients with Major Depressive Disorder: Are We Considering All the Options?
Author(s):
This activity is supported by an educational grant from Mylan Specialty, LP.
Megan Maroney, PharmD
Clinical Assistant ProfessorErnest Mario School of PharmacyRutgers UniversityPiscataway, New JerseyClinical Psychiatric PharmacistMonmouth Medical CenterLong Branch, New Jersey
Megan Maroney, PharmD, has no financial relationships with commercial interests to disclose related to this activity.
Pharmacy Times Office of Continuing Professional Education Planning Staff
Judy V. Lum, MPA, Ann C. Lichti, CCMEP, and Elena Beyzarov, PharmD, have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
Pharmacy Times Editorial Staff
Jennifer Whartenby and David Allikas have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
The peer reviewer of this activity has no relevant financial relationships with commercial interests to disclose related to this activity.
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Review the pathophysiology and epidemiology of major depressive disorder (MDD), atypical depression, and treatment-resistant depression.
- Address challenges of treating depression, including safety concerns (eg, adverse effects, drug—food interactions), noncompliance, relapse, and inadequate response to antidepressant therapy.
- Discuss current and emerging antidepressant treatments, including strategies used for typical and treatment-resistant depression.
- Formulate counseling strategies to improve patient outcomes in depression.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: August 10, 2012
Expiration date: August 10, 2014
Estimated time to complete activity: 2 hours
Fee: This lesson is free online
Click here to view this activity.
